Home

Addressing the COVID-19 Pandemic with the Development of ARDS Therapeutic

Phase I study results has led to a FDA-approved Phase II-A clinical trial with the objective to evaluate the safety and efficacy in treating Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients.

About Pulthera

Pulthera is a US-based biopharmaceutical company that specializes in revolutionary therapeutics designed to protect against the destruction of vital tissue and organs caused by infectious pathogens, including Acute Respiratory Distress Syndrome (“ARDS”) due to COVID-19.

As the exclusive licensee of these new therapies, it is our mission to leverage the proprietary technology and therapeutics to become a global leader in the pulmonary, respiratory and lung-health field.

Addressing the Pandemic

Billions have been spent on preventing the spread of COVID-19 through vaccine development. More needs to be invested addressing those who have been (and will be) infected with COVID-19, and the long-term impact to the lungs and other vital organs.

Cytokine Storm Blocker is our proprietary therapeutic that has completed a Phase I study and has been approved by the FDA for Phase II-A clinical trial. The therapy is designed to target the Cytokine Storm during the management of Acute Respiratory Distress Syndrome (ARDS) due to COVID-19, and other infectious pathogens. Phase II-III clinical trials will determine if our therapy can:

  • Eliminate or reduce need for COVID-19 patients who develop ARDS to be placed on mechanical ventilators
  • Protect and repair lung tissue from damaged caused by ARDS in COVID-19 patients
  • Improve clinical outcomes for COVID-19 patients who develop respiratory infections

Beyond the Pandemic

Lung-related medical conditions impact hundreds of millions of patients globally each year, with medical costs in the multi-billions of dollars.

  • COPD is the third leading cause of death in the United States with a treatment market in excess of $70 billion
  • Asthma effects over 24 million in the US with a treatment market in excess of $15 billion
  • Other possible indications include: Pneumonia, Pulmonary Fibrosis, Cystic Fibrosis, and more…

Pulthera therapeutic products are uniquely positioned to address many of these conditions, and we working to design clinical trials to validate the safety and efficacy of our treatments in human subjects.

Take Action Now

Pulthera is seeking to raise $100 million dollars to advance the following objectives:

  • Complete the FDA approved Phase II-A clinical trial for ARDS in COVID-19 patients
  • Implement Phase II-III clinical trial and achieve FDA Emergency Use Authorization for treatment of ARDS in COVID-19 patients
  • Accelerate commercial manufacturing capabilities, and
  • Advance the clinical application of at least one other lung-related medical condition

Pulthera seeks to leverage its proprietary technology and therapeutics to become a global leader in the pulmonary, respiratory and lung-health field.

Contact Us for more information:

James Snider, CEO – jgsnider1@gmail.com